Navigation Links
Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Date:8/27/2007

TORONTO, Aug. 27 /PRNewswire/ -- Drug Royalty LP 2 (DRC) announced today the purchase of 25% of Enzon Pharmaceuticals, Inc.'s (ENZN) worldwide royalty interest in PEG-INTRON for $92.5M. DRC will also provide a $15M milestone payment in 2012 should certain royalty recognition levels be met. PEG-INTRON (peginterferon alpha-2b), is approved for the treatment of Hepatitis C and is marketed worldwide by Schering-Plough Corporation (SGP).

Speaking on behalf of DRC, Paul Kirkconnell, Managing Director, said: "DRC is very pleased to be working with Enzon Pharmaceuticals. We believe that PEG- INTRON is one of the most advanced medications to treat Hepatitis C on the market today." Kirkconnell added, "With access to significant capital and a long track record in completing royalty transactions, we take pride in meeting the needs of pharmaceutical companies such as Enzon."

About PEG-INTRON(R)

PEG-INTRON is a PEG-enhanced version of Schering-Plough's alpha interferon product, INTRON(R) A, which is used both as a monotherapy and in combination with REBETOL(R) (ribavirin) capsules for the treatment of chronic hepatitis C. Under Enzon's license agreement with Schering-Plough, Schering-Plough holds an exclusive worldwide license to PEG-INTRON, and Enzon receives royalties on worldwide sales of PEG-INTRON. Schering-Plough is responsible for all manufacturing, marketing, and development activities for PEG-INTRON. Enzon designed PEG-INTRON to allow for less frequent dosing and to yield greater efficacy, as compared to INTRON A. PEG-INTRON is marketed worldwide by Schering-Plough and its affiliates.

About Drug Royalty Corporation, Inc. (DRC)

Drug Royalty Corporation ("DRC") is a privately held investment management company, focused on the healthcare industry, with over $1 billion under management. DRC currently manages two funds: the Royalty Monetization Fund and the Structured Finance Fund.

Its Royalty Monetization Fund acquires existing roya
'/>"/>

SOURCE Drug Royalty Corporation, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Speaker announces business members of IT Task Force
11. Doyle announces technology tax credits for Berbee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 AcelRx ... specialty pharmaceutical company focused on the development and ... acute and breakthrough pain, today announced that it ... results after market close on Monday, March 9th, ... call at 4:30 p.m. Eastern Time (1:30 p.m. ...
(Date:3/4/2015)... 2015 Vegalab announced the acquisition of Ecowin, ... year. As part of the acquisition, Ecowin rebranded itself ... his role as CEO for the company,s Korea operations. ... work alongside Koo and oversee developments at the new ... Koo founded Ecowin in 2008 to ...
(Date:3/4/2015)... Launched by the Assistance Publique - ... 2011, ,SARAH, - the French national collaborative randomized ... advanced hepatocellular carcinoma (HCC) has enrolled more than 400 ... a large French study of patients with advanced, inoperable ... patient enrolment, exceeding its 400-patient target, according to its ...
(Date:3/4/2015)... 2015   ... und Therapie, Strahlendosismanagement und IT-Lösungen für die gesamte ... Philips (NYSE: PHG, AEX: PHIA) gab heute ... (ECR) bekannt, der vom 4. bis 8. März in ... Ständen Nr. 102 and 110 wird das ...
Breaking Biology Technology:AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6
... & Associates, a San,Diego-based regulatory affairs and drug ... on diabetes and related metabolic diseases,during the months ... Food and,Drug Administration officials Dr. Alexander Fleming and ... of other guest speakers and panelists., Researchers ...
... from PAREXEL,International Corporation (Nasdaq: PRXL ), ... on key topics at the,Drug Information Association,s ... held March 3 - 5, 2008. Attendees ... thought leaders, selected by the DIA to,address ...
... scientific ... meetings, ... antibody fragment therapeutics, today announced that it has,achieved high concentrations of ... via eye drops. These data were confirmed in,several independent preclinical in ...
Cached Biology Technology:The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics 2PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting 2PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting 3PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting 4ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops 2ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops 3
(Date:2/10/2015)... -- Alere Inc. (NYSE: ALR), a global leader in ... quarter ended December 31, 2014. Namal ... said, "We made substantial progress in the fourth ... in rapid diagnostics and delivering against our financial ... early January enabled us to substantially reduce our ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
(Date:2/5/2015)... LA JOLLA, Calif. , Jan. 30, 2015 /PRNewswire/ ... realizes the great power and potential for genomic science ... to aid in disease prevention and treatment.  I was ... a potential new, government-funded precision medicine program. ... on advancing the science of genomics—from the first sequenced ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... of Veterinary Medicine have identified a gene in Labrador retriever ... After intense hunting or retrieving exercise, activities these dogs are ... their hind limbs. In most cases, their legs get ... the dogs may die. Labradors are the most common ...
... Harbor Laboratory (CSHL) have succeeded in tracing intricate biochemical ... to express themselves in specific tissues at particular moments ... and Adrian R. Krainer, Ph.D., both professors at CSHL ... biologists and geneticists call RNA splicing. Splicing is ...
... A person,s trash can reveal valuable information, as ... a cell,s "trash" may yield certain treasures, University ... new technique they developed, scientists at UD,s Delaware ... of the world,s most-studied plants and discovered formerly ...
Cached Biology News:U of M researchers identify gene linked to common ailment in labrador retrievers 2CSHL team traces extensive networks regulating alternative RNA splicing 2CSHL team traces extensive networks regulating alternative RNA splicing 3CSHL team traces extensive networks regulating alternative RNA splicing 4Using novel tool, UD researchers dig through cell 'trash' and find treasure 2Using novel tool, UD researchers dig through cell 'trash' and find treasure 3
... CE-based system provides clear advantages over ... load, gene expression), mutation analysis, and ... system with microplate connectivity is ideal ... quality control. The P/ACE Series ...
The imaging screen-K (Kodak), is a 35 x 43 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
... Kit is a 2-color staining method for ... to detect apoptotic cells by flow cytometry. ... required for measuring apoptosis in cells, including ... reagent performance; washing, reaction and rinsing buffers ...
Biology Products: